Half-Matched stem cell transplant offers hope for sickle cell control
NCT ID NCT03077542
First seen Apr 29, 2026 · Last updated May 20, 2026 · Updated 5 times
Summary
This study tests a stem cell transplant from a half-matched family donor to treat sickle cell disease in adults. The goal is to see if the new, gentler transplant method is safe and can stop severe complications like strokes. Participants receive low-dose radiation and immune-suppressing drugs before the donor cells are infused. After the transplant, they must stay near the hospital for 3 months and be followed for 5 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.